http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Abbott (ABT) FreeStyle Libre Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries
-
Abbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries
-
Abbott (ABT) Announces FDA Clearance of Reader for FreeStyle Libre 3 System
-
FDA Clears Reader for Abbott's FreeStyle Libre® 3 System
-
Abbott Hosts Conference Call for First-Quarter Earnings
-
Don't Mess with Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get it Checked' in New Public Service Announcement
-
Abbott (ABT) Receives FDA Clearance for First Commercially Available Lab-based Blood Test to Help Evaluate Concussion
-
Abbott Receives FDA Clearance for First Commercially Available Lab-based Blood Test to Help Evaluate Concussion
-
Abbott (ABT) Announces FDA Clearance of FreeStyle Libre 2 and FreeStyle Libre 3 Sensors
-
Krystal Biotech (KRYS) Appoints Catherine Mazzacco to its Board
-
U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems
-
Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device
-
New Data Show Superiority of Abbott's TriClip™ Device Compared to Medical Therapy for Tricuspid Regurgitation
-
Abbott (ABT) Says Late-Breaking Data Reinforce Benefits of Minimally Invasive Heart Devices
-
Late-Breaking Data Reinforce Benefits of Abbott's Minimally Invasive Heart Devices
-
Abbott Declares 397th Consecutive Quarterly Dividend
-
Abbott (ABT) to acquire Cardiovascular Systems (CSII) for $20/share
-
Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results
-
Abbott to Acquire Cardiovascular Systems, Inc.
-
Abbott (ABT) Announces FDA Approves Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
-
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
-
Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
-
Abbott (ABT) Wins FDA Approval for Navitor
-
Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis
-
Abbott, Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation
-
Abbott Hosts Conference Call for Fourth-Quarter Earnings
-
Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany
-
Abbott to Present at J.P. Morgan Healthcare Conference
-
Abbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain
-
Abbott and the Brain Injury Association of America launch Concussion Awareness Now coalition; team up with Rebel Wilson to raise awareness on seriousness of concussions
-
Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth
-
Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology
-
Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation
-
Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance
-
Abbott and The Home Edit Redesign the Medicine Cabinet to Help People Prepare for the Upcoming Virus Season
-
New Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life
-
Abbott Hosts Conference Call for Third-Quarter Earnings
-
Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies
-
Abbott Declares 395th Consecutive Quarterly Dividend
-
Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery
-
New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
-
Abbott (ABT) Announces FDA Approval for New Proclaim Plus Spinal Cord Stimulation
-
FDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions
-
New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions
-
Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals
-
Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance
-
Abbott (ABT) Granted FDA's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression
-
Abbott Receives FDA's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression
-
Abbott Hosts Conference Call for Second-Quarter Earnings
-
Abbott Declares 394th Consecutive Quarterly Dividend

